novo glp 1 drugs US FDA accepts Nordisk's application for oral Wegovy for weight loss Novo Nordisk plans to slash

Chronic Disease Prevalence : Rising global rates of type 2 diabetes and obesity are expanding the patient pool for GLP1 therapies, increasing demand for both glycemic and weight management indications

Look for sections titled "prescription drug coverage," "weight management," or "obesity treatment." Some plans explicitly exclude "anti-obesity medications" or "weight loss drugs" in a separate exclusion section, even if other prescription medications are covered

For analysts, this affects three basic metrics: Initiation : who can start treatment when the monthly cost is high

[DOI] [PMC free article] [PubMed] [Google Scholar] 174.Frates B

The ingredients havent been studied in these populations, so its best to wait

Patent filings have concentrated on sequence optimization, receptor balance, and dosing regimens [5, 6], while scientific reviews increasingly position these compounds as the next frontier beyond single-target GLP-1 therapy [1, 2]